Artecoll: A long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects. Discussion

Plastic and Reconstructive Surgery

Volumn 114, Issue 4, 2004, Pages 977-979

  Fagien, Steven ^a   Born, Trevor M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTECOLL; BOTULINUM TOXIN A; COLLAGEN IMPLANT; FILLER; POLY(METHYL METHACRYLATE); UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BLINDNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FACE DEFORMITY; GRANULOMA; HUMAN; IMPLANT; INJECTION; LIP; MAJOR CLINICAL STUDY; METHODOLOGY; MORBIDITY; MULTICENTER STUDY; NECROSIS; NOTE; PRIORITY JOURNAL; PURIFICATION; RANDOMIZED CONTROLLED TRIAL; SAFETY; TECHNIQUE; WRINKLE;

EID: 14944382809     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PRS.0000133704.62119.D9     Document Type: Note

References (12)

1. Hanke, C. W. Adverse reactions to bovine collagen. In A. W. Klein (Ed.), Tissue Augmentation in Clinical Practice: Procedures and Techniques. New York: Marcel Dekker, 1998. Pp. 145-154.
2. Klein, A. W. In favor of double skin testing. J. Dermatol. Surg. Oncol. 15: 263, 1989.
3. Fagien, S. Facial soft-tissue augmentation with injectable autologous and allogeneic human tissue collagen matrix (Autologen and Dermalogen). Plast. Reconstr. Surg. 105: 362, 2000.
4. Lemperle, G., Gauthier-Hazan, N., and Lemperle, M. PMMA microspheres (Artecoll) for long-lasting correction of wrinkles: Refinements and statistical results. Aesthetic Plast. Surg. 22: 365, 1998.
5. Lemperle, F., Morhenn, V., and Charrier, U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast. Surg. 27: 354, 2003.
6. Ridley, H. Intra-ocular acrylic lenses. Trans. Ophthalmol. Soc. U. K. 71: 617, 1951.
7. Lemperle, G. L. Personal communication. May 2004.
8. Wortman, M. From the chief scientific officer, Medicis Aesthetics. Personal communication. January 2004.
9. Hylaform PMA PO30032; Genzyme Corp. David Krause; Biologist/Expert Reviewer FDA. November 3, 2003.
10. Canderm Pharma, Inc. Artecoll: Incidents of events. Montreal, Canada: Canderm Pharma, 2004.
11. U.S. Food and Drug Administration. Panel recommendations, 2004.
12. Cucin, R. L., and Barek, D. Complications of injectable collagen implants. Plast. Reconstr. Surg. 71: 731, 1983.